Thinly traded nano cap Anthera Pharmaceuticals (NASDAQ:ANTH) is up9%premarket on increased volume in response to its announcement that its Phase 3 RESULT study assessing Sollpura (liprotamase) for exocrine pancreatic insufficiency due to cystic fibrosis has been approved by the European Cystic Fibrosis Society Clinical Trial Network Executive Committee, a decision that should expedite patient recruitment. <\/p>\n
Top-line are expected as early as year-end. <\/p>\n
Sollpurais a non-porcine pancreatic enzyme replacement therapy (PERT) containing a proprietary engineered cross-linked formulation of crystalline lipase, crystalline protease and amorphous amylase. The company says its solubility and stability offers a more patient-friendly alternative for those who cannot swallow multiple pills or require gastric tubes in order to maintain their nutritional health. <\/p>\n
Previously: Anthera's Sollpura on par with Pancreaze in extension phase of late-stage study in certain CF patients; shares ahead 9% after hours (March 29) <\/p>\n
<\/p>\n
See the article here:<\/p>\n
Anthera's late-stage study of Sollpura to be included in European CF network; shares ahead 9% premarket - Seeking Alpha<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Thinly traded nano cap Anthera Pharmaceuticals (NASDAQ:ANTH) is up9%premarket on increased volume in response to its announcement that its Phase 3 RESULT study assessing Sollpura (liprotamase) for exocrine pancreatic insufficiency due to cystic fibrosis has been approved by the European Cystic Fibrosis Society Clinical Trial Network Executive Committee, a decision that should expedite patient recruitment. Top-line are expected as early as year-end. Sollpurais a non-porcine pancreatic enzyme replacement therapy (PERT) containing a proprietary engineered cross-linked formulation of crystalline lipase, crystalline protease and amorphous amylase. Continue reading